TNXP · Tonix Pharmaceuticals Holding Corp.

This filing represents a high-materiality clinical development milestone for Tonix Pharmaceuticals, marking the transition of TNX-4800 from Phase 1 safety and pharmacokinetic characterization into late-stage field efficacy evaluation. The Phase 1 study (NCT04863287) enrolled 44 healthy adults and demonstrated favorable tolerability — all drug-related adverse events were mild or moderate except one severe event deemed not drug-related — and robust PK properties, including rapid detection at two days post-dose and a mean half-life of 62–69 days, supporting the feasibility of a two-dose, six-month protection strategy. Critically, the Company has aligned its Phase 2 design around these findings: a fixed subcutaneous dose intended to deliver exposure comparable to the 5 mg/kg cohort from Phase 1, administered in Spring and boosted two months later. The planned adaptive, randomized, double-blind, placebo-controlled field study targets adolescents and adults aged 16+ in U.S. Lyme-endemic areas, with the primary endpoint being prevention of confirmed Lyme disease over six months — a clinically meaningful and regulatory-relevant measure. The timing hinges on FDA agreement, to be sought via a Type C meeting in early Q3 2026, and GMP material availability in early 2027. Given that TNX-4800 is positioned as the only late-stage passive immunization candidate for Lyme disease prevention — with mechanistic advantages over active vaccines (e.g., no reliance on host immune response, rapid onset, simplified dosing) and no currently approved alternatives — successful execution of this Phase 2 program could materially de-risk the asset and establish a potential near-term catalyst for valuation inflection.